Molecular typing is predicated on molecular genetic screening and is not yet routinely readily available. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple destructive) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 might https://edgarl429ipx7.oblogation.com/profile